Cephalexin

證據等級: L5

預測適應症: 10 個

Cephalexin: From Bacterial Infections to Chronic Otitis Media

One-Sentence Summary

Cephalexin is a first-generation oral cephalosporin antibiotic with proven bactericidal activity against gram-positive organisms, widely used globally for common bacterial infections such as skin and soft tissue infections, urinary tract infections, and respiratory tract infections.

The TxGNN model predicts it may be effective for Chronic Otitis Media, with 0 registered clinical trials and 20 publications currently supporting this direction — predominantly older observational studies and one direct double-blind RCT from 1983.

The strength of this prediction is tempered by a key mechanistic limitation: cephalexin provides incomplete coverage against Haemophilus influenzae and Moraxella catarrhalis, two pathogens central to the pathogenesis of chronic otitis media, which modern guidelines address with broader-spectrum agents.

Quick Overview

Item	Content
Original Indication	No SAHPRA registration data available (known globally as a first-generation cephalosporin for bacterial infections)
Predicted New Indication	Chronic Otitis Media
TxGNN Prediction Score	98.55%
Evidence Level	L3
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Cephalexin is a first-generation cephalosporin that exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs), thereby disrupting bacterial cell wall synthesis and causing cell lysis. It is well absorbed orally, achieves therapeutic concentrations in most tissues, and has a long-established safety record. Its activity is particularly strong against gram-positive cocci such as Streptococcus pneumoniae and Staphylococcus aureus — both recognised contributors to middle ear infections, particularly in the pre-antibiotic era literature.

The mechanistic connection to chronic otitis media rests on the fact that bacterial colonisation of the middle ear space — by S. pneumoniae, S. aureus, and to a lesser extent anaerobes — represents the primary driver of disease in a subset of patients with chronic suppurative otitis media (CSOM). Literature from the 1970s and 1980s documents direct clinical use of cephalexin (referred to as CEX in Japanese ENT literature) as a comparator drug in trials of acute and chronic suppurative otitis media, and one study (PMID 6798820) specifically measured bacterial count reduction in COM patients treated with oral versus topical cephalexin.

However, there is a critical mechanistic limitation that explains why cephalexin has largely been displaced in this indication: first-generation cephalosporins provide unreliable coverage against Haemophilus influenzae and Moraxella catarrhalis — organisms responsible for a substantial proportion of CSOM cases — partly due to intrinsic resistance and partly due to beta-lactamase production. Contemporary ENT guidelines therefore favour amoxicillin-clavulanate or second/third-generation cephalosporins. The TxGNN model’s high prediction score likely reflects the drug’s proximity to “middle ear infection” nodes in the knowledge graph rather than a novel mechanistic insight.

Clinical Trial Evidence

Currently no clinical trials for cephalexin specifically in chronic otitis media are registered on ClinicalTrials.gov or the WHO ICTRP.

Literature Evidence

The following publications were identified from the PubMed search. Priority has been given to studies with the highest tier classification and those directly involving cephalexin or its immediate cephalosporin predecessors in otitis media.

PMID	Year	Type	Journal	Key Findings
6361325	1983	RCT (Double-blind)	Japanese Journal of Antibiotics	Cefroxadine vs cephalexin (CEX 250 mg qid) in acute suppurative otitis media and acute exacerbation of CSOM; both drugs produced comparable clinical outcomes with no statistically significant difference
22737435	2011	Cross-sectional study	Iranian Red Crescent Medical Journal	Aerobic microorganism isolation from CSOM patients in Iran; documented current antimicrobial susceptibility patterns, with implications for empirical antibiotic selection
8177625	1994	Clinical comparative study	Pediatric Infectious Disease Journal	69 children with CSOM; mixed aerobic/anaerobic flora in 54% of cases; beta-lactamase-producing bacteria in 58% of patients; anaerobic-effective therapy showed fastest resolution
6798820	1981	Microbiological observational study	Acta Oto-Laryngologica	Direct study of cephalexin (CEX) in COM: oral vs ear drops; ear drops produced higher bacterial count reduction; minimum bactericidal concentrations documented
7200999	1982	Pharmacokinetic study	Journal of Infectious Diseases	Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and TMP-SMX into middle ear fluid of 83 children with chronic serous otitis media; provides pharmacodynamic context for cephalosporin class
1920724	1991	Observational study	JAMA	Bacteriology of acute otitis media in adults in the US; H. influenzae prevalence in adults studied for the first time; contextualises pathogen spectrum relevant to antibiotic selection
2685215	1989	Observational study	Nihon Jibiinkoka Gakkai Kaiho	193 children with OME; 30% culture-positive; antibiotic courses studied; respiratory pathogens detected in 17% of ears
11838568	2001	Review	Indian Journal of Pediatrics	Comprehensive review of upper RTIs; otitis media constitutes 87.5% of all respiratory infection episodes; the vast majority are viral, limiting antibiotic utility
12017394	2002	Narrative review	Clinical Therapeutics	Review of cefdinir (3rd-gen cephalosporin) approved for acute bacterial otitis media; broader H. influenzae and M. catarrhalis coverage compared to first-generation agents illustrates the progression beyond cephalexin
15212560	2004	Systematic review	Drugs	Cefdinir systematic review; good activity against H. influenzae, M. catarrhalis, and penicillin-susceptible S. pneumoniae; stable against plasmid-mediated beta-lactamases — contrasting with cephalexin’s narrower spectrum

South Africa Market Information

Cephalexin is not currently registered with SAHPRA and has no active product licences in South Africa. There are no registration numbers, dosage forms, or SAHPRA-approved indications to report.

Note: Cephalexin is a widely available generic oral antibiotic in many other countries (including the UK, USA, India, and Australia) and is included on the WHO Essential Medicines List as a first-generation cephalosporin. Its absence from the South African register is a significant practical barrier to any local clinical programme.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information — noting that no South African PI currently exists for this product. Prescribers should consult the manufacturer’s global Professional Information and international references (e.g., FDA label, BNF). Adverse drug reactions should be reported to SAHPRA via the MedSafety system.

The following class-level safety considerations are clinically relevant based on the published literature reviewed:

Cross-reactivity: Cephalexin belongs to the beta-lactam class. Patients with documented penicillin allergy (particularly immediate hypersensitivity reactions) require caution; cross-reactivity risk is low but not negligible.
Allergic reactions: Case reports in the retrieved literature (PMID 9470025, PMID 10103342) describe severe allergic reactions including hypersensitivity myocarditis and anaphylaxis associated with related cephalosporins (cefaclor). Equivalent reactions to cephalexin have been reported in the literature.
Antimicrobial stewardship: Use in viral otitis media (the majority of cases) represents inappropriate antibiotic use and contributes to resistance; treatment decisions should be guided by microbiological confirmation where possible.

Conclusion and Next Steps

Decision: Hold

Rationale: Cephalexin has historical plausibility for bacterial otitis media (including chronic suppurative forms) based on its PBP-inhibiting mechanism and older comparative clinical trial data, but its spectrum of activity is insufficient for the full range of pathogens implicated in chronic otitis media — particularly beta-lactamase-producing H. influenzae and M. catarrhalis — and modern ENT guidelines have moved to broader-spectrum alternatives. Critically, cephalexin is not registered with SAHPRA and is not available on the South African market, making clinical development or formulary consideration impractical without regulatory groundwork.

To proceed, the following would be needed:

SAHPRA registration: A product dossier submission would be required before any clinical use in South Africa; this is a prerequisite step with significant lead time.
Mechanism of action data (MOA): Formal DrugBank API retrieval and literature review to document PBP binding specificity and pharmacodynamic/pharmacokinetic profile against South African CSOM pathogen isolates.
South African microbiology data: Local antimicrobial susceptibility data for middle ear pathogens (ideally from NHLS or local ENT service surveillance) to assess whether cephalexin’s spectrum is relevant in the South African epidemiological context.
Comparative effectiveness review: A head-to-head protocol comparing cephalexin with amoxicillin-clavulanate (the current standard) would be required to establish clinical non-inferiority — any such study should be registered with SANCTR (South African National Clinical Trials Register) and considered for PACTR registration.
Safety profile review: Full SAHPRA-format PI and prescriber information should be developed, drawing on global regulatory data.

Research note for investigators: The TxGNN model’s predictions for ranks 4–10 (otosalpingitis, non-suppurative otitis media, allergic otitis media, cholesterol granuloma, polyclonal hyperviscosity syndrome, hyperamylasemia, congenital analbuminemia) all received a Hold recommendation and are not discussed further in this report. These either lack mechanistic plausibility for a first-generation antibiotic, represent graph propagation artefacts in the TxGNN knowledge graph, or in the case of allergic otitis media, carry an active safety concern — the retrieved literature describes cephalosporin-induced allergic reactions rather than treatment of the condition.

This report is generated for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. This document does not replace SAHPRA-approved prescribing information. Healthcare professionals should refer to the applicable regulatory authority’s guidance for clinical decision-making.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.